Wall Street May Be Mispricing Medtronic, Analyst Says

Medtronic reported Q4 earnings that beat expectations with adjusted EPS of $1.55 and revenue of $9.81 billion, up 9.9% year-over-year. BTIG upgraded the stock from Neutral to Buy with a $90 price target, citing consistent organic growth and undervaluation relative to peers. Leerink Partners lowered its price target from $117 to $104 but maintains an Outperform rating, highlighting MDT as a Top Pick for 2026. Shares rose 4.30% to $81.30.